CERVICAL CANCER SCREENING PROGRAMME

Reporting year for qualitative data:	2021
Source of qualitative data:	Directly from Programme

Organization of screening
An individual/team/institution responsible to coordinate the programme:	Yes
Dedicated budget for screening programme:	Yes
Documented cancer screening policy:	Yes
Nature of documentation of the policy:	Recommendation
Year programme was initiated:	2009
Programme introduction was preceded by a pilot:	Yes, status unknown
Screening tests provided free of charge:	Yes
Diagnostic tests provided free of charge:	Yes
Treatment services provided free of charge:	Yes
Information system and data collection
System that collects data:	Aggregated
• Identification of eligible population:	-
• Screening participation:	Aggregated
• Screening test results:	Aggregated
• Further assessment:	Aggregated
• Final pathology diagnosis:	No
• Cancer staging:	No
• Treatment:	No
The information system exists at national or sub-national level:	Individual: Unknown Aggregated: Both national and sub-national
The information system collects data outside the programme (opportunistic screening/private sector):	No
Cancer screening data is linked with population-based cancer registry (PBCR):	PBCR exists but not linked
Screening protocol
A screening protocol or guideline:	Yes
Year of published/updated protocol:	2018
Target age (min-max) and screening interval [months] for each test:	VIA (25-49 years / [36 months])
Triaging test used:	None
Self-collection HPV recommended:	-
"Screen and treat" included in the protocol:	Yes
Treatment modality for "screen and treat":	Cryotherapy LLETZ/CKC
Invitations for screening and further assessment
Initiatives to create population awareness by the Health Ministry/Health Authority:	Small media campaign Group education One-on-one education
Invitations to eligible population:	No
Source of the eligible individuals identified:	-
Method of invitation:	-
Screening kit included with the invitation:	-
Screen positive individuals actively contacted for further assessment:	No
Individuals with a precancer or cancer diagnosis actively contacted:	No
Quality Assurance (QA) of screening activities
Documented standard operating procedure/policy for QA:	Yes
An individual/team/institution responsible for QA:	Yes
Accreditation of lab services:	Yes
Accreditation of pathology services:	Yes
Documented performance indicators:	Yes
Reference standards for performance indicators:	Yes
Evaluation reports published in the last five years:	No
Performance indicators
Reporting year for quantitative data:	2019
Source of quantitative data:	Directly from programme
Age range and regional limitation if applicable:	25-49 years
Invitation coverage (%):
Participation rate (%):
Examination coverage (%):	7.0
Completeness of data related to screening test results (%):
Completeness of data related to further assessment results (%):
Further assessment (Colposcopy referral) rate (%):	1.0
Further assessment participation rate (%):
Detection rate for CIN2+ (x 1000):
Detection rate for CIN3+ (x 1000):
Detection rate for invasive cancer (x 1000):
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):
Positive Predictive Value for CIN3+ (x 1000):
Positive Predictive Value for invasive cancer (x 1000):
More quantitative data (2019/VIA)

Check also the following factsheets: Guyana, Breast, Colorectal